Skip to content

Released Aug 11, 2023, after the close

10-Q filed Aug 11, 2023, 42 days after period end · 0000950170-23-041851

Q2 2023 · 10-Q
Revenue—
Net Income-$1.45MN/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$5.83N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$1,933,030N/M
Operating Cash Flowderived-$1,991,615N/M
Free Cash Flowderived-$1,991,615—

What the release said

The release

Same quarter

MetricQ2 2023Q2 2022Q2 2021Q2 2020
Net Income-$1.45M-$1.83M-$2.47M-$521.00
EPS Diluted-$5.83-$4.16-$0.39$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Revelation Biosciences, Inc. · CIK 1810560 · Engraved from SEC EDGAR